About Pulmatrix
Pulmatrix is a company based in Lexington (United States) founded in 2003.. Pulmatrix has raised $67.11 million across 19 funding rounds from investors including NIH, HHS and DARPA. The company has 2 employees as of December 31, 2024. Pulmatrix offers products and services including iSPERSE™, PUR3100, PUR1900, and PUR1800. Pulmatrix operates in a competitive market with competitors including aTyr Pharma, ReCode Therapeutics, InterMune, GEn1E and Verona Pharma, among others.
- Headquarter Lexington, United States
- Employees 2 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Pulmatrix, Inc.
-
Annual Revenue
$7.81 M6.96as on Dec 31, 2024
-
Net Profit
$-9.56 M32.31as on Dec 31, 2024
-
EBITDA
$-6.71 M49.42as on Dec 31, 2024
-
Total Equity Funding
$67.11 M (USD)
in 19 rounds
-
Latest Funding Round
$45 K (USD), Post-IPO
Jul 09, 2020
-
Investors
NIH
& 9 more
-
Employee Count
2
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Pulmatrix
Pulmatrix is a publicly listed company on the NASDAQ with ticker symbol PULM in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Pulmatrix
Pulmatrix offers a comprehensive portfolio of products and services, including iSPERSE™, PUR3100, PUR1900, and PUR1800. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Innovative platform for pulmonary drug delivery to treat serious diseases.
Drug candidate for respiratory treatments in clinical development.
Pipeline drug for pulmonary disease management and innovation.
Advanced therapeutic in the company's pipeline for disease applications.
Unlock access to complete
Unlock access to complete
Funding Insights of Pulmatrix
Pulmatrix has successfully raised a total of $67.11M across 19 strategic funding rounds. The most recent funding activity was a Post-IPO round of $45 thousand completed in July 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 19
- Last Round Post-IPO — $45,000
-
First Round
First Round
(01 Jun 2004)
- Investors Count 10
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2020 | Amount | Post-IPO - Pulmatrix | Valuation |
investors |
|
| Apr, 2020 | Amount | Post-IPO - Pulmatrix | Valuation |
investors |
|
| Feb, 2019 | Amount | Post-IPO - Pulmatrix | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Pulmatrix
Pulmatrix has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, HHS and DARPA. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital fund backed incubator focused on the healthcare startups
|
Founded Year | Domain | Location | |
|
Venture capital firm focused on life science companies
|
Founded Year | Domain | Location | |
|
US focused venture capital firm
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Pulmatrix
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Pulmatrix
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Pulmatrix Comparisons
Competitors of Pulmatrix
Pulmatrix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as aTyr Pharma, ReCode Therapeutics, InterMune, GEn1E and Verona Pharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Protein biologics are developed for treating rare diseases.
|
|
| domain | founded_year | HQ Location |
Precision medicines for lung-related diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapies in pulmonology and orphan fibrotic diseases.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for the treatment of inflammatory and rare diseases
|
|
| domain | founded_year | HQ Location |
Respiratory disease drugs for asthma and COPD are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Pulmatrix
Frequently Asked Questions about Pulmatrix
When was Pulmatrix founded?
Pulmatrix was founded in 2003 and raised its 1st funding round 1 year after it was founded.
Where is Pulmatrix located?
Pulmatrix is headquartered in Lexington, United States. It is registered at Lexington, Kentucky, United States.
Is Pulmatrix a funded company?
Pulmatrix is a funded company, having raised a total of $67.11M across 19 funding rounds to date. The company's 1st funding round was a Post-IPO of $2.49M, raised on Jun 01, 2004.
How many employees does Pulmatrix have?
As of Dec 31, 2024, the latest employee count at Pulmatrix is 2.
What is the annual revenue of Pulmatrix?
Annual revenue of Pulmatrix is $7.81M as on Dec 31, 2024.
What does Pulmatrix do?
Developer of therapeutics for the treatment of respiratory diseases. The company offers inhaled cationic airway lining modulator drugs, which stimulate host defense mechanisms within the airway to treat and prevent influenza, rhinovirus, and chronic pulmonary diseases. The company uses an inhaled dry powder platform, iSPERSE (inhaled small particles easily respirable and emitted) to engineer particles with high dispersibility. Its product portfolio includes PUR1900, an inhaled anti-fungal product candidate for CF; PUR1500 for the treatment of idiopathic pulmonary fibrosis (IPF) which intends to suppress the fibrotic pathway at the site of disease in the lung interstitium and PUR0200 for COPD.
Who are the top competitors of Pulmatrix?
Pulmatrix's top competitors include aTyr Pharma, ReCode Therapeutics and GEn1E.
What products or services does Pulmatrix offer?
Pulmatrix offers iSPERSE™, PUR3100, PUR1900, and PUR1800.
Is Pulmatrix publicly traded?
Yes, Pulmatrix is publicly traded on NASDAQ under the ticker symbol PULM.
Who are Pulmatrix's investors?
Pulmatrix has 10 investors. Key investors include NIH, HHS, DARPA, Arch Venture Partners, and 5AM Ventures.
What is Pulmatrix's ticker symbol?
The ticker symbol of Pulmatrix is PULM on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.